论文部分内容阅读
目的比较恩替卡韦和拉米夫定治疗HBe Ag阴性乙型肝炎相关慢加急性肝衰竭患者的临床疗效。方法从2010年12月~2012年12月本溪钢铁集团南地医院收治的HBe Ag阴性乙型肝炎相关慢加急性肝衰竭患者中选取112例为研究对象,随机分成恩替卡韦组和拉米夫定组,每组56例,分别给予恩替卡韦和拉米夫定治疗。对两组患者治疗前和治疗12周后的Hbe Ag滴度、HBV DNA拷贝数、Tbil、整体治疗效果以及不良反应发生情况进行比较和观察。结果治疗前,两组患者各项数据比较差异均无显著统计学意义(P>0.05);治疗12周后,恩替卡韦组患者的各项指标水平均明显优于拉米夫定组,且组间数据比较差异均有显著的统计学意义(P均<0.05)。结论采用恩替卡韦治疗HBe Ag阴性乙型肝炎相关慢加急性肝衰竭的短期临床效果较好,好转率高,肝功能指标改善明显。
Objective To compare the clinical efficacy of entecavir and lamivudine in the treatment of patients with HBe Ag-negative hepatitis B associated with chronic and acute liver failure. Methods From December 2010 to December 2012 Benxi Iron and Steel Group Hospital South HBeAg-negative patients with chronic hepatitis B and acute liver failure were selected 112 cases were randomly divided into entecavir group and lamivudine group , 56 cases in each group, were given entecavir and lamivudine treatment. The Hbe Ag titers, HBV DNA copy number, Tbil, overall curative effect and incidence of adverse reactions were compared and observed before and 12 weeks after treatment in both groups. Results Before treatment, there was no significant difference between the two groups (P> 0.05). After 12 weeks of treatment, the levels of each index of entecavir group were significantly better than that of lamivudine group, The differences of data were statistically significant (all P <0.05). Conclusion The short-term clinical effect of entecavir in the treatment of HBeAg-negative hepatitis B-associated chronic and acute liver failure is better, the improvement rate is high, and the indexes of liver function are improved obviously.